A pair of clinical-stage biotechs made advisory and conference moves on Wednesday, with Genflow Biosciences securing an invitation to present animal longevity data in Toronto and Coiled Therapeutics bolstering its Medical Advisory Board with two oncology specialists ahead of planned trial expansion later this year.
Genflow invited to present aged-dog gene therapy results in Toronto
Genflow Biosciences (GENF) has been invited to present clinical results from its aged-dog gene therapy study at the inaugural Animal Longevity Summit in Toronto, scheduled for 1-2 October. The presentation will bring Genflow's sirtuin-6 gene therapy data before an audience focused on longevity science, marking the company's first appearance at a dedicated animal longevity forum. The shares edged down 2.74% to 2.0667p on the day.
Coiled Therapeutics strengthens oncology advisory board ahead of trial expansion
Coiled Therapeutics (COIL) has appointed Professor Guru Sonpavde and Dr Alexander Spira as founding members of its Medical Advisory Board, adding specialist oncology expertise as the company's TACC3-targeting drug approaches expansion cohorts in the second half of 2026. Both advisers bring clinical trial experience in solid tumours, providing guidance on patient selection and study design as Coiled moves its programme forward. The stock was quoted at 10.0p.
